Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Nov 16, 2018
SOUTH PLAINFIELD, N.J. , Nov. 16, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 13 , 2018 it approved non-statutory stock options to purchase an aggregate of 75,200 shares of its common stock to 19 new employees.
Additional Formats
Nov 05, 2018
-Completed acquisition of Agilis Biotherapeutics gene therapy platform- -In-licensed two rare disease therapies from Akcea Therapeutics- SOUTH PLAINFIELD, N.J. , Nov. 5, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for
Additional Formats
Oct 30, 2018
SOUTH PLAINFIELD, N.J. , Oct. 30, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Credit Suisse 27 th Annual Healthcare Conference on Tuesday, November 13 th at 10:55 a.m. MST .
Additional Formats
Oct 23, 2018
SOUTH PLAINFIELD, N.J. , Oct. 23, 2018 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on October 17 , 2018 it approved non-statutory stock options to purchase an aggregate of 68,700 shares of its common stock to 13 new employees.
Additional Formats
Oct 22, 2018
SOUTH PLAINFIELD, N.J. , Oct. 22, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2018 financial results and provide an update on the company's business and outlook on Monday, November 5,
Additional Formats
Oct 06, 2018
- Analysis of data to date shows Translarna Preserved Ambulation for up to 5 Years Compared to Natural History - SOUTH PLAINFIELD, N.J. , Oct. 6, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced preliminary data from the first international drug registry for Duchenne
Additional Formats
Oct 03, 2018
- Babies from FIREFISH Part 1 study showed increased survival & gains in developmental milestones - - SUNFISH Part 1 study demonstrated a 3.1-point increase in motor function as measured by MFM32 - - Pivotal portion of SUNFISH Part 2 study in Type 2 & 3 patients has completed enrollment - SOUTH
Additional Formats
Sep 28, 2018
SOUTH PLAINFIELD, N.J. , Sept. 28, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on September 25, 2018 it approved non-statutory stock options to purchase an aggregate of 122,200 shares of its common stock to 33 new employees.
Additional Formats
Sep 25, 2018
SOUTH PLAINFIELD, N.J. , Sept. 25, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Chardan Genetic Medicines Conference on Tuesday, October 9 th at 2:00 p.m. EST . The presentation will be webcast live on the Events and
Additional Formats
Sep 13, 2018

SOUTH PLAINFIELD, N.J. , Sept. 13, 2018 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at Jefferies Gene Therapy Summit on Thursday, September 27 th at 1:30 p.m. EST . The presentation will be webcast live on the Events and

Additional Formats